Filing Flows › Sarepta Therapeutics (SRPT) › Elevidys revenue
Sarepta Therapeutics (SRPT) Elevidys revenue by quarter
Sarepta Therapeutics' Elevidys revenue was $83.5M in Q3 2026 (third quarter 2026), -15% from Q2 2026. Over the last 6 quarters it ranged from $83.5M (Q3 2026) to $282M (Q2 2025).
| Quarter | Elevidys revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $83.5M | -15% | -37% |
| Q2 2026 | $98.1M | -4% | -65% |
| Q1 2026 | $102M | -8% | — |
| Q4 2025 | $110M | -16% | — |
| Q3 2025 | $131M | -53% | — |
| Q2 2025 | $282M | — | — |
Q3 2026 at a glance
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sarepta Therapeutics' Elevidys revenue?
Sarepta Therapeutics' Elevidys revenue was $83.5M in Q3 2026 (third quarter 2026), -15% from Q2 2026.
How has Sarepta Therapeutics' Elevidys revenue changed?
Over the last 6 quarters it ranged from $83.5M (Q3 2026) to $282M (Q2 2025).